about
Synthesis of Paclitaxel. 2. Construction of the ABCD Ring and Formal SynthesisCrystal structure of (+)-methyl (E)-3-[(2S,4S,5R)-2-amino-5-hy-droxy-meth-yl-2-tri-chloro-methyl-1,3-dioxolan-4-yl]-2-methyl-prop-2-enoate.Crystal structures of (±)-(1SR,5SR,6SR,7SR,10SR,11SR,13RS,14SR)-13-hy-droxy-7-meth-oxy-meth-oxy-11,15,18,18-tetra-methyl-3-oxo-2,4-dioxa-tetra-cyclo-[12.3.1.0(1,5).0(6,11)]octa-dec-15-en-10-yl benzoate, its 13-epimer and 13-one derivative.Crystal structure of (±)-(1SR,5SR,6SR,7SR,10SR,11SR,13SR)-13-benz-yloxy-7-meth-oxy-meth-oxy-11,15,18,18-tetra-methyl-3-oxo-2,4-dioxa-tetra-cyclo-[12.3.1.0(1,5).0(6,11)]octa-deca-14,16-dien-10-yl benzoate.Crystal structure of (-)-methyl (R,E)-4-[(2R,4R)-2-amino-2-tri-chloro-methyl-1,3-dioxolan-4-yl]-4-hy-droxy-2-methyl-but-2-enoate.Crystal structure of (±)-(4RS,5RS,7SR)-4-[(1RS,2RS,3RS,6RS)-3-benzo-yloxy-2-(2-hy-droxy-ethyl)-6-meth-oxy-meth-oxy-2-methyl-cyclo-hex-yl]-8,10,10-trimethyl-2-oxo-1,3-dioxa-spiro-[4.5]dec-8-en-7-yl benzoate benzene monosolvateCrystal structure of (+)-N-[(1R,5S,6S,9S)-5-hydroxy-methyl-3,3,9-trimethyl-8-oxo-2,4,7-trioxabi-cyclo-[4.3.0]nonan-9-yl]acetamideCrystal structure of (±)-(5SR,6SR)-6-ethenyl-1-[(RS)-1-phenyl-eth-oxy]-1-aza-spiro-[4.5]decan-2-one.Crystal structure of (±)-(7RS,8SR)-7-methyl-1,4-dioxa-spiro-[4.5]decane-7,8-diol(5R*)-5-[(2S*,5S*)-1-Meth-oxy-5-phenyl-pyrrolidin-2-yl]-3-methyl-furan-2(5H)-one.(+)-(1S,5R,6R)-6-[(S)-1-Hy-droxy-2-(meth-oxy-meth-yloxy)eth-yl]-1-methyl-3-trichloro-methyl-2-aza-4,7-dioxa-bicyclo-[3.3.0]oct-2-en-8-one.Novel sequential sigmatropic rearrangements of allylic diols: application to the total synthesis of (-)-kainic acid.Synthesis of (+)- and (-)-nojirimycin and their 1-deoxy derivatives from myo-inositol.Total synthesis of spicamycin.Cascade- and orthoamide-type Overman rearrangements of allylic vicinal diols.Practical synthesis of the C-ring precursor of paclitaxel from 3-methoxytoluene.Unified Total Synthesis of Madangamines A, C, and E.Two-step synthesis of multi-substituted amines by using an N-methoxy group as a reactivity control element.Enantioselective Total Synthesis of (+)-Neostenine.Total synthesis of (±)-gephyrotoxin by amide-selective reductive nucleophilic addition.Recent Advances in the Synthesis of Morphine and Related AlkaloidsTotal synthesis of (+)-lycoricidine and its 2-epimer from D-glucoseTotal synthesis of (+/-)-murrayazolineTotal synthesis of (-)-salinosporamide ATotal synthesis of broussonetine F: the orthoamide Overman rearrangement of an allylic diolDirect chemoselective allylation of inert amide carbonylsConcise synthesis of α-trisubstituted amines from ketones using N-methoxyaminesTotal synthesis of (-)-agelastatin A: the application of a sequential sigmatropic rearrangementA direct entry to substituted N-methoxyamines from N-methoxyamides via N-oxyiminium ionsSynthesis of Paclitaxel. 1. Synthesis of the ABC Ring of Paclitaxel by SmI2-Mediated CyclizationDirect nucleophilic addition to N-alkoxyamidesSynthesis of (-)-morphine: application of sequential Claisen/Claisen rearrangement of an allylic vicinal diolChemoselective reductive nucleophilic addition to tertiary amides, secondary amides, and N-methoxyamidesCopper-catalyzed electrophilic amination using N-methoxyaminesSynthesis of (±)-Lasubine II Using N-MethoxyaminesTotal synthesis of sphingofungin F by orthoamide-type overman rearrangement of an unsaturated esterSynthesis of diazatricyclic common structure of madangamine alkaloidsIridium-catalyzed chemoselective reductive nucleophilic addition to N-methoxyamidesSynthesis of natural products containing cyclohexane units utilizing the Ferrier carbocyclization reactionNucleophilic addition to N-alkoxyamides
P50
Q29038395-1247A8C8-155E-426A-8578-2A5AB9D9BEC4Q38786737-5344C04B-559C-4D81-A18C-C03C440E62A4Q40278778-5C7D0667-FC03-4480-B9D1-27C3765E7E43Q40281395-CC06B903-846E-4671-BEF8-FAC757CBE363Q40953291-2F2926EF-A4D0-4B05-8405-8B2143EED599Q41851221-95AABC14-1E1D-44F0-B9B8-07BB9F67A909Q41994983-7D1E354E-7A2E-4244-85C7-DD96B58D632AQ41995062-69CCC0CE-F49B-464C-A916-B2A8ADA7A1E5Q41995113-2CD0D5F7-C164-44A4-ABCF-BE46198350B0Q41996149-FD216985-9046-40BF-A3FC-7AB263DD0881Q41996872-183F1198-BEF2-4B3E-B94B-491379E4D20CQ42792921-8D802A4B-CEFA-425B-B11B-F2D10ACFE6B4Q43945005-E5BCEDB3-ED83-4320-B4D6-749DFAFB5CD3Q43970679-8FBCBB8A-FAC7-443C-8495-B45BC2FCF99EQ44451133-C5518BFE-C525-407E-9A46-82C0CDC38D9EQ46598396-9BD863D6-9267-4CE3-989A-44329319AAF8Q48249583-E134D524-D08F-4800-927D-EF6160A8E9A7Q51732375-CC284E6B-D9EA-4578-94D5-830E277CDAC6Q53642449-754ACCDF-FD04-4E18-AB23-7FE77532D0D3Q54519070-AD910F60-0D2D-4840-ADD3-713AE3A88A64Q56448658-EC90D245-9EF9-455D-89ED-E01C34193BF9Q63347153-8CEBCC08-B4B5-4506-8B00-00FFBCC3CD6CQ81055408-661A5674-AAD8-4891-9B3F-EF011ED78759Q82354862-F95A068C-1A43-44CB-B94D-CBAB0F558659Q83073430-A8E5ADFC-FC5F-4BD0-AE12-E30FBC80C70BQ83283921-F2012715-2205-4434-A2AB-49719F7356F3Q83808786-000A70B8-EFBA-426E-B885-DFFC60946616Q83850302-E044F7A5-A629-4732-8D16-2FC0AA5BD720Q84620007-76D09F73-D14E-48F4-9DD4-E695F54AB3BAQ85211945-D1E9FD48-A253-4CAB-86E1-74FBEF22B2FFQ85487061-B07D3CB6-72DF-4346-9C9F-09626A5B1E1FQ85527057-4AD2172D-BC60-44B1-8512-D2F8F6934AAEQ85856061-BAAE248E-BE45-4321-8C70-3B010712B855Q86648462-C5E0102A-CDAE-448E-B2A4-9D9FAFE8E215Q86727496-0B8DF3FE-D92B-4C68-B072-E3CEBBB0F079Q86924290-9DE481C1-4EB0-4FBB-B561-8EAE03689A92Q87006305-838311BB-14C9-411C-95E5-C038E69CC7C3Q87006503-DD53DB14-B2E4-472D-8A4D-FAEA72C8EE86Q87418845-3D66C7AD-E271-46C4-A55D-F666F543A38EQ87673622-902737E3-7584-482F-99C8-3C848778E053
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Noritaka Chida
@ast
Noritaka Chida
@en
Noritaka Chida
@es
Noritaka Chida
@nl
Noritaka Chida
@sl
type
label
Noritaka Chida
@ast
Noritaka Chida
@en
Noritaka Chida
@es
Noritaka Chida
@nl
Noritaka Chida
@sl
prefLabel
Noritaka Chida
@ast
Noritaka Chida
@en
Noritaka Chida
@es
Noritaka Chida
@nl
Noritaka Chida
@sl
P106
P108
P1153
7006060448
P31
P496
0000-0003-3074-6914